Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Gains from Investment Securities (2017 - 2025)

Moleculin Biotech's Gains from Investment Securities history spans 9 years, with the latest figure at -$24.4 million for Q4 2025.

  • Quarterly results put Gains from Investment Securities at -$24.4 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was -$26.0 million (down 42087.1% YoY), and the annual figure for FY2025 was $191854.0, up 511.37%.
  • Gains from Investment Securities for Q4 2025 was -$24.4 million at Moleculin Biotech, down from -$1.6 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $1.5 million in Q3 2023 to a low of -$24.4 million in Q4 2025.
  • The 5-year median for Gains from Investment Securities is $21667.0 (2022), against an average of -$1.5 million.
  • The sharpest move saw Gains from Investment Securities plummeted 502.0% in 2022, then soared 11212.06% in 2025.
  • Year by year, Gains from Investment Securities stood at -$1000.0 in 2021, then surged by 84383.2% to $842832.0 in 2022, then crashed by 88.02% to $101000.0 in 2023, then tumbled by 98.96% to $1053.0 in 2024, then plummeted by 2321182.62% to -$24.4 million in 2025.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at -$24.4 million, -$1.6 million, and $119116.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.